As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a study reporting 14-year results from the LONGTERMS study which trialled Fingolimod for relapsing MS.
Independent expert commentary is provided by Professor Tomas Kalincik, the Dame Kate Campbell Professorial Fellow, the head of the Clinical Outcomes Research (CORe) Unit at the University of Melbourne and of the MS Centre at the Royal Melbourne Hospital.
Please login below to download this issue (PDF)